Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triamcinolone acetonide + yttrium-90
- Development stage
- Unknown
- Lead developer
- Harrow
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intraarticular
01
Overview
A combination therapy consisting of triamcinolone acetonide (a synthetic glucocorticoid) and yttrium-90 (a radioactive isotope). This combination is administered as an intra-articular injection to treat chronic pyrophosphate arthropathy. The triamcinolone component provides anti-inflammatory effects while the yttrium-90 delivers targeted radiation therapy to the affected joint.
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on triamcinolone acetonide + yttrium-90.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triamcinolone acetonide + yttrium-90.